This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Natalizumab (NTZ) (Tysabri; Biogen Idec/Elan, Cambridge, MA) is a monoclonal immunoglobulin G antibody against alpha-4-integrins, which is prescribed in France to patients with multiple sclerosis (MS) who have experienced at least one relapse during a 1-year therapy with interferon beta, an increase in the T2 lesion load and gadolinium enhancement, or in naïve patients who have experienced at least two relapses and have MRI evidence of active disease.1 Adverse effects described with NTZ include most frequently intolerance-induced perfusion in up to 15% of treated patients, and hypersensitivity reactions in 4% of treated patients during or within 1 hour after perfusion, mainly during the first infusion.1,2 Development of persistent anti-NTZ antibodies is also reported in 6% of treated patients and is associated with an increased risk of developing a hypersensitivity reaction or MS relapse. To date, cardiovascular toxicity with NTZ has not been reported, except for cardiovascular manifestations associated with hypersensitivity such as tachycardia.
We report a case of pericarditis, an adverse effect that has never …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study
Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
SEVERE CUTANEOUS CANDIDA INFECTION DURING NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS